Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00174629
Status:
COMPLETED
Last Update Posted:
2009-12-07
First Post:
2005-09-09
Brief Title:
GILT Docetaxel - Non-Small Cell Lung Cancer
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Open-Label Cooperative Randomized Multicenter Phase III Study on the Use of Cisplatin Resistant Genotype ERCC1 Over-Expression in Tumor RNA to Customize Chemotherapy in Stage IV-IIIB Malignant Pleural Effusion Non-Small-Cell Lung Cancer Patients
Status:
COMPLETED
Status Verified Date:
2009-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary Objective
To compare response rate between genotypic groups and control group
Secondary Objective
To determine the safety time to treatment failure and survival in control and genotypic arms
To compare response rate between genotypic groups and control group
Secondary Objective
To determine the safety time to treatment failure and survival in control and genotypic arms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None